Acriflavine-empowered IR780-PTX albumin nanoparticles for reinforced synergistic photochemotherapy

Abstract

Traditional chemotherapy and radiotherapy for glioma are challenging due to the hypoxia in tumor microenvironment and the inability of chemotherapeutic agents to enter into tumor cells. Phototherapy is a novel therapeutic approach against various tumors in recent years. When combined with chemotherapy, the antitumor efficacy of phototherapy is superior than each alone. However, the combination of chemotherapy and phototherapy is still hampered by the hypoxic tumor microenvironment which upregulates the expression of hypoxia-inducible factor 1 (HIF-1) and its downstream pathways, as well as the thermoresistance caused by the overexpression of heat shock proteins (HSPs). To solve this, the biocompatible albumin-based nanoparticles (NPs) are developed to co-deliver IR780 iodine (IR780) and paclitaxel (PTX) simultaneously at an optimized ratio (IR780-PTX NPs) for synergistic photochemotherapy. Moreover, acriflavine (ACF), a chemical inhibitor of HIF-1, is formulated into intratumorally formed hydrogels to reinforce synergistic photochemotherapy. The continuously released ACF from hydrogel not only relieves the impact of photodynamic therapy-exacerbated tumor hypoxia by suppressing HIF-1 activity, but also efficiently attenuates HSP70 upregulation. The collaboration between IR780-PTX NPs and ACF hydrogels leads to an extraordinary antitumor effect in vitro and in vivo. The reinforced synergistic photochemotherapy via a single molecule by overcoming HIF-1 activity and HSP overexpression provides an effective therapeutic example to treat tumors, especially in those undergone severe hypoxia and/or therapy-induced thermoresistance.

Keywords

Glioma / Albumin nanoparticles / Photochemotherapy / Hypoxia / Thermoresistance

References

[1] Blum R, Jacob-Hirsch J, Amariglio N, Rechavi G, Kloog Y. Ras inhibition in glioblastoma down-regulates hypoxia-inducible factor-1α, causing glycolysis shutdown and cell death. Cancer Res. 2005, 65(3): 999-1006.

[2] Cai Y, Chai T, Nguyen Wet al. . Phototherapy in cancer treatment: strategies and challenges. Signal Transduct Target Ther. 2025, 10(1): 115.

[3] Cao X, Li S, Chen Wet al. . Multifunctional hybrid hydrogel system enhanced the therapeutic efficacy of treatments for postoperative glioma. ACS Appl Mater Interfaces. 2022, 142427623-27633.

[4] Cao Y, Ren Q, Hao R, Sun Z. Innovative strategies to boost photothermal therapy at mild temperature mediated by functional nanomaterials. Mater des. 2022, 214. 110391

[5] Cao Y, Jin L, Zhang Set al. . Blood-brain barrier permeable and multi-stimuli responsive nanoplatform for orthotopic glioma inhibition by synergistic enhanced chemo-/chemodynamic/photothermal/starvation therapy. Eur J Pharm Sci. 2023, 180: 106319.

[6] Chao Y, Xu L, Liang Cet al. . Combined local immunostimulatory radioisotope therapy and systemic immune checkpoint blockade imparts potent antitumour responses. Nat Biomed Eng. 2018, 2(8): 611-621.

[7] Chen Z, Li S, Li Fet al. . DNA damage inducer mitoxantrone amplifies synergistic mild-photothermal chemotherapy for TNBC via decreasing heat shock protein 70 expression. Adv Sci. 2023, 1016e2206707.

[8] Ding K, Tian H, Li Let al. . Drug repurposing-based nanoplatform via modulating autophagy to enhance chemo-phototherapy against colorectal cancer. J Nanobiotechnology. 2024, 221202.

[9] Domènech M, Hernández A, Plaja A, Martínez-Balibrea E, Balañà C. Hypoxia: the cornerstone of glioblastoma. Int J Mol Sci. 2021; 22(22).

[10] Dube T, Kompella UB, Panda JJ. Near infrared triggered chemo-PTT-PDT effect mediated by glioma directed twin functional-chimeric peptide-decorated gold nanoroses. J Photochem Photobiol B. 2022, 228: 112407.

[11] Guo J, Wang MF, Yuan SJet al. . Photo-controlled co-delivery of verteporfin and acriflavine via platelets achieves potentiated glioblastoma-targeted photodynamic therapy. J Nanobiotechnol. 2025, 231371.

[12] He M, Zhang M, Xu T, et al. Enhancing photodynamic immunotherapy by reprograming the immunosuppressive tumor microenvironment with hypoxia relief. J Control Release. 2024;368:233–50.

[13] Iqbal H, Yang T, Li Tet al. . Serum protein-based nanoparticles for cancer diagnosis and treatment. J Control Release. 2021, 329997-1022.

[14] Jin Y, Liang L, Sun Xet al. . Deoxyribozyme-nanosponges for improved photothermal therapy by overcoming thermoresistance. NPG Asia Materials. 2018, 105373-384.

[15] Jung E, Kwon S, Song Net al. . Tumor-targeted redox-regulating and antiangiogenic phototherapeutics nanoassemblies for self-boosting phototherapy. Biomaterials. 2023, 298: 122127.

[16] Karschnia P, Nelson TA, Dietrich J. Mechanisms and treatment of cancer therapy-induced peripheral and central neurotoxicity. Nat Rev Cancer. 2025, 25(12): 887-909.

[17] Ke G, Hu P, Xiong Het al. . Enhancing temozolomide efficacy in GBM: the synergistic role of chuanxiong rhizoma essential oil. Phytomedicine. 2025, 140: 156575.

[18] Li X, Kwon N, Guo T, Liu Z, Yoon J. Innovative strategies for hypoxic-tumor photodynamic therapy. Angew Chem Int Ed Engl. 2018, 573611522-11531.

[19] Li T, Li J, Chen Zet al. . Glioma diagnosis and therapy: Current challenges and nanomaterial-based solutions. J Control Release. 2022, 352: 338-370.

[20] Li X, Zhang W, Fang Yet al. . Large-scale CRISPRi screens link metabolic stress to glioblastoma chemoresistance. J Transl Med. 2025, 231289.

[21] Lim JS, Shi Y, Park SHet al. . Mutual regulation between phosphofructokinase 1 platelet isoform and VEGF promotes glioblastoma tumor growth. Cell Death Dis. 2022, 13111002.

[22] Liu W, Di J, Ma Y, et al. Mitochondria-mediated HSP inhibition strategy for enhanced low-temperature photothermal therapy. ACS Appl Mater Interfaces. 2023;15(22):26252–62.

[23] Liu L, Tu B, Sun Yet al. . Nanobody-based drug delivery systems for cancer therapy. J Control Release. 2025, 381: 113562.

[24] Lu L, Zhao X, Fu Tet al. . An iRGD-conjugated prodrug micelle with blood-brain-barrier penetrability for anti-glioma therapy. Biomaterials. 2020, 230119666.

[25] Ma S, Wang F, Dong Jet al. . Inhibition of hypoxia-inducible factor 1 by acriflavine renders glioblastoma sensitive for photodynamic therapy. J Photochem Photobiol B. 2022, 234112537.

[26] Moon EJ, Sonveaux P, Porporato PEet al. . NADPH oxidase-mediated reactive oxygen species production activates hypoxia-inducible factor-1 (HIF-1) via the ERK pathway after hyperthermia treatment. Proc Natl Acad Sci U S A. 2010, 1074720477-20482.

[27] Murphy G, Brayden DJ, Cheung DLet al. . Albumin-based delivery systems: recent advances, challenges, and opportunities. J Control Release. 2025, 380: 375-395.

[28] Overchuk M, Weersink RA, Wilson BC, Zheng G. Photodynamic and photothermal therapies: synergy opportunities for nanomedicine. ACS Nano. 2023, 1797979-8003.

[29] Park HB, An EK, Kim SJet al. . Anti-PD-L1 antibody fragment linked to tumor-targeting lipid nanoparticle can eliminate cancer and its metastasis via photoimmunotherapy. ACS Nano. 2024, 18(49): 33366-33380.

[30] Patrizii M, Bartucci M, Pine SR, Sabaawy HE. Utility of glioblastoma patient-derived orthotopic xenografts in drug discovery and personalized therapy. Front Oncol. 2018, 8: 23.

[31] Ren X, Zhao B, Chang Het al. . Paclitaxel suppresses proliferation and induces apoptosis through regulation of ROS and the AKT/MAPK signaling pathway in canine mammary gland tumor cells. Mol Med Rep. 2018, 17(6): 8289-8299

[32] Ruan C, Liu L, Lu Yet al. . Substance P-modified human serum albumin nanoparticles loaded with paclitaxel for targeted therapy of glioma. Acta Pharm Sin B. 2018, 8185-96.

[33] Schaff LR, Mellinghoff IK. Glioblastoma and other primary brain malignancies in adults: a review. JAMA. 2023, 329(7): 574-587.

[34] Su X, Xie Y, Zhang Jet al. . HIF-α activation by the prolyl hydroxylase inhibitor roxadustat suppresses chemoresistant glioblastoma growth by inducing ferroptosis. Cell Death Dis. 2022, 13(10): 861.

[35] Sun H, Zhang J, Qi Het al. . Ioning out glioblastoma: ferroptosis mechanisms and therapeutic frontiers. Cell Death Discov. 2025, 111407.

[36] Tedeschi BBB, Henrique T, Vila APSet al. . Evaluation of hypoxia-inducible factor-1 and 2 alpha inhibitory compounds in the oral cavity and pharyngeal cancer. Biomed Pharmacother. 2025, 186: 118024.

[37] Wang M, He M, Zhang M, Xue S, Xu T, Zhao Y, Li D, Zhi F, Ding D. Controllable hypoxia-activated chemotherapy as a dual enhancer for synergistic cancer photodynamic immunotherapy. Biomaterials. 2023;301:122257.

[38] Wang T, Chen G, Zhang Set al. . Steerable microneedles enabling deep delivery of photosensitizers and CRISPR/Cas9 systems for effective combination cancer therapy. Nano Lett. 2023, 23177990-7999.

[39] Wang Y, Yue C, Zhang Met al. . Dually enhanced phototherapy by gambogic acid and hyperthemia-activated chemotherapy for synergistic breast cancer treatment. Chem Eng J. 2023, 452: 139108.

[40] Wei Y, Wan Y, Duan S, Hu Q, Xu N. Lupeol induces apoptosis of glioma cells via governing ubiquitination-mediated SPARC turnover. Tissue Cell. 2025, 97103039.

[41] Wu S, Gao M, Chen Let al. . A multifunctional nanoreactor-induced dual inhibition of HSP70 strategy for enhancing mild photothermal/chemodynamic synergistic tumor therapy. Adv Healthc Mater. 2024, 1323e2400819.

[42] Xu T, Liu K, Mi Set al. . Cyclooxygenase-2/prostaglandin E2 inhibition remodulated photodynamic therapy-associated immunosuppression for enhanced cancer immunotherapy. Materials Today Bio. 2025, 31101530.

[43] Yadav B, Wennerberg K, Aittokallio T, Tang J. Searching for drug synergy in complex dose-response landscapes using an interaction potency model. Comput Struct Biotechnol J. 2015, 13504-513.

[44] Yang N, Xiao W, Song X, Wang W, Dong X. Recent advances in tumor microenvironment hydrogen peroxide-responsive materials for cancer photodynamic therapy. Nano-Micro Lett. 2020, 121. 15

[45] Yang Z, Du Y, Sun Qet al. . Albumin-based nanotheranostic probe with hypoxia alleviating potentiates synchronous multimodal imaging and phototherapy for glioma. ACS Nano. 2020, 1456191-6212.

[46] Yang Z, Du Y, Lei Let al. . Co-delivery of ibrutinib and hydroxychloroquine by albumin nanoparticles for enhanced chemotherapy of glioma. Int J Pharm. 2023, 630: 122436.

[47] Yun HJ, Li M, Guo Det al. . AMPK-HIF-1α signaling enhances glucose-derived de novo serine biosynthesis to promote glioblastoma growth. J Exp Clin Cancer Res. 2023, 421340.

[48] Zeng B, Pian L, Liu Yet al. . Preparation and effects of functionalized liposomes targeting breast cancer tumors using chemotherapy, phototherapy, and immunotherapy. J Nanobiotechnology. 2024, 221558.

[49] Zhang S, Li Q, Yang Net al. . Phase-change materials based nanoparticles for controlled hypoxia modulation and enhanced phototherapy. Adv Funct Mater. 2019, 29491906805.

[50] Zhang X, He C, Liu Xet al. . One-pot synthesis of a microporous organosilica-coated cisplatin nanoplatform for HIF-1-targeted combination cancer therapy. Theranostics. 2020, 1072918-2929.

[51] Zhang X, He C, Xiang G. Engineering nanomedicines to inhibit hypoxia-inducible factor-1 for cancer therapy. Cancer Lett. 2022, 530: 110-127.

[52] Zhang H, Zhu W, Pan Wet al. . Recent advances in spatio-temporally controllable systems for management of glioma. Asian J Pharm Sci. 2024, 195100954

[53] Zhu L, Liu J, Qiu Met al. . Bacteria-mediated metformin-loaded peptide hydrogel reprograms the tumor immune microenvironment in glioblastoma. Biomaterials. 2022, 288121711.

[54] Zhu S, Sun F, Zhao Pet al. . Brain-targeting biomimetic nanoparticles for codelivery of celastrol and LY2157299 for reversing glioma immunosuppression. Int J Pharm. 2022, 619121709.

Funding

Changzhou High-Level Health Talents Training Project(2022260)

Changzhou Science and Technology Project(CJ20230062)

Research Development Fund of Xi’an Jiaotong-Liverpool University(RDF-24-02-082)

National Natural Science Foundation of China(32330060)

RIGHTS & PERMISSIONS

The Author(s)